Skip to content
value.today

Foghorn Therapeutics Inc.

FHTX
$123 Mmarket cap on Oct 28, 2026-52.0% since Jan 2024
Compare
World rank
#18,011
Revenue
$31 M
For year ending December-2025
Net income
$-74 M
-240.3% margin
SEC filing
Employees
85
As on August 2020
value.today research

Foghorn Therapeutics Inc. in brief

Foghorn Therapeutics Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. Its market value was $123 M on 28 October 2026, which makes it the 18,011th largest listed company in the world and the 3,413th largest in the USA on this site. In the year to December 2025 it had sales of $31 M and a net loss of $74 M. It employs about 85 people and Adrian Gottschalk is its chief executive. Its largest business segments by sales in 2025 were The (100%). Its shares trade under the symbol FHTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is Developing Therapies designed to modulate the chromatin regulatory system company. The company estimated annual revenue is currently 17.8 million USD per year and 85 employees as on 2020. The headquarters is in USA.

Foghorn Therapeutics Inc. timeline

3 events, 2020–2023
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 23 October 2020; shares registered for exchange trading on 19 October 2020.
  4. 2023
  5. 💰
    Record revenue of $34 million
    FY2023, the highest of the 6 years on record.

Events of Foghorn Therapeutics Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$201 M$402 M$603 M$805 M202120222023202420252026

World rank over time

▼ down 8,806 places since 2021
2021-01-01: #9242#9,24220212022-01-07: #11175#11,17520222022-12-25: #17091#17,09120222023-07-30: #14495#14,49520232024-01-05: #16627#16,62720242026-03-08: #8165#8,16520262026-08-01: #13398#13,39820262026-10-28: #18048#18,0482026

Rank in USA: #2,433 (Jan 2021) · #2,851 (Jan 2022) · #3,493 (Dec 2022) · #2,951 (Jul 2023) · #3,063 (Jan 2024) · #1,469 (Mar 2026) · #2,719 (Aug 2026) · #3,417 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
4.0×
Price / book
—
Free cash flow yield
-70.1%
Net margin
-240.3%
Operating margin
-279.5%
Return on equity
—
Liabilities / assets
154.8%
Net debt
$-101M
Revenue growth
+36.8%
R&D / revenue
276.5%
Revenue per employee
$364 K
Profit per employee
$-874 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-51M—FY19Fiscal year ending Dec 2020: revenue $0M, net income $-69M$0MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-101M$1MFY21Fiscal year ending Dec 2022: revenue $19M, net income $-109M$19MFY22Fiscal year ending Dec 2023: revenue $34M, net income $-98M$34MFY23Fiscal year ending Dec 2024: revenue $23M, net income $-87M$23MFY24Fiscal year ending Dec 2025: revenue $31M, net income $-74M$31MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$31M+36.8%$-86M$-74M-240.3%
Dec 2024$23M-33.8%$-103M$-87M-383.3%
Dec 2023$34M+77.6%$-108M$-98M-288.1%
Dec 2022$19M+1356.8%$-117M$-109M-566.2%
Dec 2021$1M+207.0%$-101M$-101M-7675.8%
Dec 2020$0M—$-69M$-69M-16000.0%
Dec 2019——$-51M$-51M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-86M$0M$-86M$-1.18—
Dec 2024$-100M$1M$-101M$-1.58—
Dec 2023$-118M$1M$-119M$-2.34—
Dec 2022$194M$1M$192M$-2.62—
Dec 2021$-50M$3M$-54M$-2.73—
Dec 2020$-31M$16M$-47M$-6.23—
Dec 2019$-46M$1M$-47M$-12.20—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $3M, net income $-20M$3MDec ’24Three months to Mar 2025: revenue $6M, net income $-19M$6MMar ’25Three months to Jun 2025: revenue $8M, net income $-18M$8MJun ’25Three months to Sep 2025: revenue $8M, net income $-16M$8MSep ’25Three months to Dec 2025 (from the annual report): revenue $9M, net income $-22M$9MDec ’25Three months to Mar 2026: revenue $3M, net income $-20M$3MMar ’26Three months to Jun 2026: revenue $16M, net income $-7M$16MJun ’26Three months to Sep 2026: revenue $84M, net income $58M$84MSep ’26

Latest quarter to Sep 2026: revenue $84M (+925.0% on a year earlier), net income $58M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Foghorn Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$31 M
Operating income
$-86 M
Net income
$-74 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$198 M
Total liabilities
$307 M
Total equity
$-109 M

As of December-2025

Top 100 institutional investors in Foghorn Therapeutics Inc.#

As of Sep 30, 2026
122 institutions held 47.1 M shares (about 78.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 64.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Foghorn Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Flagship Pioneering, LLC12,674,1200 (0.00%)21.14%$45 MNov 16, 2026
2BVF Inc/il5,842,0000 (0.00%)9.74%$21 MNov 16, 2026
3FMR LLC5,546,349-159,609 (-2.80%)9.25%$20 MNov 10, 2026
4Deerfield Management Company, L.P.4,394,3670 (0.00%)7.33%$16 MNov 16, 2026
5BlackRock, Inc.3,065,236+438,404 (+16.69%)5.11%$11 MNov 13, 2026
6Raymond James Financial Inc2,479,621-10,357 (-0.42%)4.14%$9 MNov 12, 2026
7Vanguard Capital Management LLC1,586,219+91,608 (+6.13%)2.65%$6 MNov 13, 2026
8Euclidean Capital LLC1,573,7610 (0.00%)2.62%$6 MNov 16, 2026
9Geode Capital Management, LLC861,655-49,211 (-5.40%)1.44%$3 MNov 6, 2026
10Siren, L.L.C.720,7200 (0.00%)1.20%$3 MNov 12, 2026
11State Street Corp692,290-5,179 (-0.74%)1.15%$2 MNov 12, 2026
12Jpmorgan Chase & Co643,533+623,100 (+3049.48%)1.07%$2 MNov 12, 2026
13Qube Research & Technologies Ltd540,315+337,019 (+165.78%)0.90%$2 MNov 13, 2026
14Renaissance Technologies LLC432,339+54,403 (+14.39%)0.72%$2 MNov 12, 2026
15Vanguard Portfolio Management LLC338,066+33,634 (+11.05%)0.56%$1 MNov 13, 2026
16Jacobs Levy Equity Management, Inc321,284+15,850 (+5.19%)0.54%$1 MNov 16, 2026
17Northern Trust Corp316,432+6,657 (+2.15%)0.53%$1 MNov 16, 2026
18Candriam S.C.A.313,7650 (0.00%)0.52%$1 MNov 3, 2026
19Birchview Capital, LP282,307+370 (+0.13%)0.47%$1 MNov 13, 2026
20Vanguard Fiduciary Trust Co275,130+10,708 (+4.05%)0.46%$1 MNov 13, 2026
21Goldman Sachs Group Inc234,669+70,413 (+42.87%)0.39%$1 MNov 16, 2026
22Panagora Asset Management Inc227,091+51,685 (+29.47%)0.38%$1 MNov 12, 2026
23B Group, Inc.200,0000 (0.00%)0.33%$1 MNov 16, 2026
24Morgan Stanley172,839+80,743 (+87.67%)0.29%$1 MNov 13, 2026
25Ikarian Capital, LLC160,000New0.27%$1 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Foghorn Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Mackenzie Financial Corp151,354New0.25%$1 MNov 2, 2026
27Acadian Asset Management LLC151,224+112,440 (+289.91%)0.25%$1 MNov 9, 2026
28Squarepoint Ops LLC137,435+7,089 (+5.44%)0.23%$0 MNov 9, 2026
29Ameriprise Financial Inc128,536-430,149 (-76.99%)0.21%$0 MNov 16, 2026
30Charles Schwab Investment Management Inc127,072+17,291 (+15.75%)0.21%$0 MNov 16, 2026
31UBS Group AG125,524+114,293 (+1017.66%)0.21%$0 MNov 10, 2026
32SCS Capital Management LLC106,9800 (0.00%)0.18%$0 MNov 12, 2026
33Citadel Advisors LLC106,479-52,343 (-32.96%)0.18%$0 MNov 16, 2026
34Point72 Asset Management, L.P.106,201New0.18%$0 MNov 16, 2026
35DAFNA Capital Management LLC89,659-22,200 (-19.85%)0.15%$0 MNov 16, 2026
36Palumbo Wealth Management LLC88,791-2,948 (-3.21%)0.15%$0 MNov 13, 2026
37Prudential Financial Inc86,998New0.15%$0 MNov 16, 2026
38Invesco Ltd.83,313+5,178 (+6.63%)0.14%$0 MNov 12, 2026
39Millennium Management LLC82,236+28,727 (+53.69%)0.14%$0 MNov 16, 2026
40HRT Financial LP79,961New0.13%$0 MNov 13, 2026
41Trexquant Investment LP79,711New0.13%$0 MNov 16, 2026
42Bank of New York Mellon Corp77,575-1,780 (-2.24%)0.13%$0 MNov 5, 2026
43Bridgeway Capital Management, LLC77,100-12,500 (-13.95%)0.13%$0 MNov 16, 2026
44Susquehanna International Group, LLP75,361New0.13%$0 MNov 16, 2026
45Empowered Funds, LLC70,500New0.12%$0 MNov 13, 2026
46Gsa Capital Partners LLP68,501+38,995 (+132.16%)0.11%$0 MNov 16, 2026
47Nuveen, LLC67,077+2,038 (+3.13%)0.11%$0 MNov 10, 2026
48Lynx1 Capital Management LP61,5880 (0.00%)0.10%$0 MNov 16, 2026
49Boothbay Fund Management, LLC51,146New0.09%$0 MNov 16, 2026
50Verdad Advisers, LP42,049-11,182 (-21.01%)0.07%$0 MNov 16, 2026
51Rhumbline Advisers41,832+2,250 (+5.68%)0.07%$0 MNov 10, 2026
52Bank Of America Corp /de/41,488+15,385 (+58.94%)0.07%$0 MNov 16, 2026
53Engineers Gate Manager LP39,539New0.07%$0 MNov 16, 2026
54AQR Capital Management LLC37,375-28,864 (-43.58%)0.06%$0 MNov 16, 2026
55Price T Rowe Associates Inc /MD/35,194+10,716 (+43.78%)0.06%$0 MNov 16, 2026
56Graham Capital Management, L.P.32,318New0.05%$0 MNov 16, 2026
57Deutsche Bank AG\32,122-4,415 (-12.08%)0.05%$0 MNov 6, 2026
58EntryPoint Capital, LLC31,568+16,085 (+103.89%)0.05%$0 MNov 13, 2026
59Public Employees Retirement System Of Ohio31,408+29,157 (+1295.29%)0.05%$0 MNov 16, 2026
60Susquehanna Portfolio Strategies, LLC30,438New0.05%$0 MNov 16, 2026
61Jump Financial, LLC30,422-5,961 (-16.38%)0.05%$0 MNov 13, 2026
62Alliancebernstein L.P.29,7600 (0.00%)0.05%$0 MNov 16, 2026
63Barclays PLC28,766+9,577 (+49.91%)0.05%$0 MNov 6, 2026
64Canada Pension Plan Investment Board25,1000 (0.00%)0.04%$0 MNov 16, 2026
65Atom Investors LP24,950New0.04%$0 MNov 16, 2026
66Stifel Financial Corp21,616New0.04%$0 MNov 12, 2026
67Creative Planning20,710New0.03%$0 MNov 2, 2026
68Quadrature Capital Ltd20,700New0.03%$0 MNov 13, 2026
69Two Sigma Securities, LLC18,162New0.03%$0 MNov 16, 2026
70MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.17,710+888 (+5.28%)0.03%$0 MNov 16, 2026
71Two Sigma Investments, LP16,627+4,182 (+33.60%)0.03%$0 MNov 16, 2026
72Simplex Trading, LLC15,770+13,878 (+733.51%)0.03%$0 MNov 4, 2026
73Russell Investments Group, Ltd.14,853+424 (+2.94%)0.02%$0 MNov 6, 2026
74Diversified Trust Co14,8300 (0.00%)0.02%$0 MNov 6, 2026
75Axq Capital, LP14,637New0.02%$0 MNov 12, 2026
76SEI Investments Co14,457New0.02%$0 MNov 10, 2026
77Prelude Capital Management, LLC13,761New0.02%$0 MNov 16, 2026
78Wells Fargo & Company/mn13,427-21,874 (-61.96%)0.02%$0 MNov 16, 2026
79Steward Partners Investment Advisory, LLC13,417New0.02%$0 MNov 13, 2026
80HSBC Holdings PLC13,210New0.02%$0 MNov 16, 2026
81Vanguard Global Advisers, LLC13,005+172 (+1.34%)0.02%$0 MNov 13, 2026
82UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC12,793+9,917 (+344.82%)0.02%$0 MNov 16, 2026
83Centiva Capital, LP12,151New0.02%$0 MNov 13, 2026
84Strs Ohio11,700+3,100 (+36.05%)0.02%$0 MOct 30, 2026
85Manufacturers Life Insurance Company, The11,699New0.02%$0 MNov 13, 2026
86MetLife Investment Management, LLC11,374New0.02%$0 MNov 16, 2026
87Police & Firemen's Retirement System of New Jersey11,3260 (0.00%)0.02%$0 MNov 9, 2026
88XTX Topco Ltd11,043New0.02%$0 MNov 16, 2026
89China Universal Asset Management Co., Ltd.10,835+1,491 (+15.96%)0.02%$0 MOct 28, 2026
90BNP Paribas Financial Markets10,482+26 (+0.25%)0.02%$0 MNov 12, 2026
91Employees Retirement System of Texas10,324New0.02%$0 MNov 10, 2026
92Evelyn Partners Group Ltd7,1000 (0.00%)0.01%$0 MNov 10, 2026
93Citigroup Inc3,388-15,156 (-81.73%)0.01%$0 MNov 4, 2026
94Ameritas Investment Partners, Inc.3,3430 (0.00%)0.01%$0 MNov 13, 2026
95Mirae Asset Global Investments Co., Ltd.3,035+409 (+15.58%)0.01%$0 MOct 29, 2026
96Legal & General Group Plc2,9850 (0.00%)0.01%$0 MNov 16, 2026
97Tower Research Capital LLC (TRC)2,757-525 (-16.00%)0.00%$0 MNov 16, 2026
98Royal Bank Of Canada2,101+1,004 (+91.52%)0.00%$0 MNov 16, 2026
99New York State Common Retirement Fund1,8710 (0.00%)0.00%$0 MNov 17, 2026
100GF Fund Management Co. LTD.1,349+108 (+8.70%)0.00%$0 MOct 26, 2026

All 122 institutional investors, with who bought and sold →

Mutual funds holding Foghorn Therapeutics Inc.#

81 funds hold shares worth $36 M (about 9.5% of the company). Since their previous reports 33 added shares and 21 sold, buying $0 M net.
Mutual funds holding Foghorn Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC1.84 M$8 M2.2%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.03 M$5 M1.3%<0.01%+0.1%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors896,556$4 M1.1%<0.01%+13%Jun 30, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC501,007$2 M0.61%<0.01%−1.3%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.428,310$2 M0.52%<0.01%−0.3%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC396,371$2 M0.48%<0.01%+16%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors342,513$2 M0.42%0.01%+84%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC351,578$2 M0.43%0.03%−46%May 31, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC283,912$1 M0.35%<0.01%−13%May 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors221,798$1 M0.27%0.01%−0.6%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC188,248$1 M0.23%<0.01%+2.1%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.175,973$1 M0.21%<0.01%+7.1%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors122,329$1 M0.15%0.04%+39%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC83,000$0 M0.10%0.27%+22%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.87,961$0 M0.11%<0.01%+20%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC63,923$0 M0.08%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC62,113$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.53,644$0 M0.07%0.02%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC56,879$0 M0.07%<0.01%+15%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC48,322$0 M0.06%<0.01%+44%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC36,498$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC34,015$0 M0.04%0.01%+88%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC36,629$0 M0.04%<0.01%+9.4%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.30,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I28,105$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.21,128$0 M0.03%<0.01%+95%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation20,000$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.19,962$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.19,268$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.21,925$0 M0.03%<0.01%+3.1%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.19,208$0 M0.02%<0.01%+4.0%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC17,620$0 M0.02%<0.01%+9.6%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC17,433$0 M0.02%<0.01%+16%Jul 31, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.13,584$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC14,497$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS13,298$0 M0.02%0.01%−27%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.12,800$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company12,971$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC11,859$0 M0.01%0.02%−18%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC10,810$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC10,683$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC10,814$0 M0.01%<0.01%+65%Jul 31, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS9,753$0 M0.01%0.02%−28%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC9,070$0 M0.01%<0.01%+21%Jun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC8,906$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC8,883$0 M0.01%<0.01%−56%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC8,261$0 M0.01%0.02%+30%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.8,309$0 M0.01%<0.01%+20%May 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.6,629$0 M<0.01%<0.01%−4.5%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS6,573$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC6,356$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC5,873$0 M<0.01%<0.01%+48%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,422$0 M<0.01%<0.01%+49%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.5,062$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC4,422$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC4,633$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.4,268$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION4,200$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,958$0 M<0.01%<0.01%+102%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC3,375$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC3,636$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC3,340$0 M<0.01%<0.01%+33%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,343$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,577$0 M<0.01%<0.01%+5.9%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC3,280$0 M<0.01%0.01%+113%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC2,713$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC2,790$0 M<0.01%<0.01%+62%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.2,231$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,571$0 M<0.01%<0.01%+80%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,624$0 M<0.01%<0.01%+13%May 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC1,251$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,282$0 M<0.01%<0.01%−38%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,269$0 M<0.01%<0.01%−38%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,017$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.763$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC742$0 M<0.01%<0.01%−5.4%May 31, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC505$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC484$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC410$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.385$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC204$0 M<0.01%<0.01%+13%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 81 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Foghorn Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
11
since
-$781 K$0Mar 2024: bought $0 (0 trades), sold $72 K (1 trades)Mar 24Sep 2024: bought $0 (0 trades), sold $781 K (6 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Foghorn Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect-59,208——240,792Form 4
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect+59,208——270,912Form 4
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect-47,497——0Form 4
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect+47,497——211,704Form 4
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect-300,000——511,704Form 4
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect+300,000——511,704Form 4
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect-197,906——511,704Form 4
filed Adrian GottschalkChief Executive Officer, DirectorGiftindirect+197,906——511,704Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Foghorn Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.3 M
4.0% of shares · 3.9 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-10-01 10:55 UTC, code T3, resumed 11:30 UTC
  • 2024-12-16 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 2,177 shares at $2.05
  • : 1,514 shares at $1.85
  • : 14,493 shares at $2.92
  • : 51 shares at $3.52
  • : 83 shares at $5.69

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Foghorn Therapeutics Inc. scorecard#

Passes 7 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median4.0×Price to sales 4.0× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-70.1%Free cash flow is -70.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year36.8%Revenue up 36.8% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years17.1%17.1% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median17.1%17.1% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.18 vs -1.58Diluted EPS -1.18 in fiscal 2025 against -1.58 the year before (report's currency).
    • ✗Net income higher than five years earlier-$74 M-$74 M in fiscal 2025 against -$69 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$74 MNet income -$74 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-279.5%-279.5% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-279.5%-279.5% in fiscal 2025 against -609.2% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.7×Current ratio 2.73 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-4.89Z-score -4.89 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year14.7%Diluted shares up 14.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Foghorn Therapeutics Inc.'s statements, beside the median of Biotechnology.

Foghorn Therapeutics Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-279.5%-60.5%
Net margin-240.3%-68.9%
Revenue growth, 3 years a year17.1%12.9%
Revenue growth36.8%15.8%
Free cash flow margin-278.7%-61.5%

1of 7on the Piotroski tests of financial strength

  • Net loss of $74 million, the 7th loss-making year in a row.
  • Free cash flow was negative: -$86 million.
  • The share count rose 14.7% in the year.
  • Shareholders' equity is negative: -$108 million.

Foghorn Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Foghorn Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue312334191.30.4—
Research and development8595110106805844
General and administrative2828323122116.7
Operating expenses1171251421361026951
Operating income−86−103−108−117−101−69−51
Interest expense and finance costs————1.91.00.5
Other non-operating income (expense)1216148.3−0.6−0.3−0.0
Income before tax—−87−94−109———
Income tax004.20—00
Net income including minority interests—————−69−51
Net income attributable to shareholders−74−87−98−109−101−69−51
Earnings per share, basic-1.18-1.58-2.34-2.62-2.73-6.23-12.20
Earnings per share, diluted-1.18-1.58-2.34-2.62-2.73-6.23-12.20
Shares, weighted average (basic)635542423711—
Shares, weighted average (diluted)6355424237114.2
Balance sheet
Cash and cash equivalents815580521019315
Other current assets3.15.96.15.65.34.91.4
Current assets16325024035146019117
Property, plant and equipment1.910.0131518202.7
Right-of-use (leased) assets3123303439431.0
Total assets19828428640552025622
Accounts payable4.33.86.35.43.83.73.4
Debt due within a year—————04.2
Current liabilities60675855491913
Long-term debt————020r11
Lease liabilities (non-current)4028374651580.2
Total liabilities30733036340542310924
Retained earnings−632−558−472−373−264−163−94
Shareholders' equity−109−46−770.197146−88
Total liabilities and equity19828428640552025622
Shares outstanding5756424241374.9
Cash-flow statement
Depreciation and amortization3.33.13.53.33.21.30.7
Share-based compensation101216148.43.01.7
Cash from operating activities−86−100−118194−50−31−46
Capital expenditure−0.1−0.9−1.2−1.2−3.3−16−1.0
Cash from investing activities112−30144−24436−109−1.0
Shares issued—1030————
Cash from financing activities1.01051.81.82221724
Report10-K10-K10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Foghorn Therapeutics Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • The$31 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Foghorn Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.4 M
Mr. Gottshalk
Other top executives, average
$1.2 M
the CEO earned 2× this
$100 invested is now
$84
Foghorn Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Gottshalk$2.4 M$3.1 M$1.2 M$84
2024Adrian Gottschalk$1.6 M$2.4 M$1.7 M$73

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Foghorn Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Restructuring 1 · Directors and officers 5 · Material agreement 1 · Agreement ended 1 · Shareholder vote 2 · Results announced 11

Foghorn Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Restructuring8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officersResults announced8-K
Results announced8-K
Material agreementAgreement ended8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

H-1B hiring at Foghorn Therapeutics Inc.#

9 labor condition applications certified in fiscal 2026 for 9 positions, at a median wage of $135 K a year.

Certified, FY2026
9
#859 among companies on value.today
Worker positions
9
Median wage offered
$135 K
a year, full-time
Applications filed
9
Foghorn Therapeutics Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior ScientistMolecular and Cellular Biologists3$135 K
Principal Research AssociateChemists2$106 K
ScientistChemists2$129 K
Senior Scientist, BioinformaticsBioinformatics Scientists2$135 K

Where: Watertown, MA 9

Foghorn Therapeutics Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202699$135 K9
FY202511$126 K1
FY202366$125 K6
FY202288$125 K8
FY202133$122 K3
FY202022$61 K3

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Foghorn Therapeutics, Inc.

Layoffs at Foghorn Therapeutics Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2026–2026
Latest
—
2026-09-25
Foghorn Therapeutics Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
Foghorn Therapeutics Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
40% of workforceRestructuring planSEC 8-K“In connection with this decision, the Company announced a reduction in its workforce by approximately 40% of its current workforce.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Foghorn Therapeutics Inc. compares in Biotechnology

  • Market cap$123 M · higher than 39% of 726
  • Revenue$31 M · higher than 54% of 647
  • Net margin-240.3% · higher than 24% of 408
  • Revenue growth36.8% · higher than 69% of 438
  • Price / sales4.0× · lower than 68% of 339
  • FCF yield-70.1% · higher than 17% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Foghorn Therapeutics Inc.🇺🇸$123 M—-240.3%+36.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on August 2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Foghorn Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Foghorn Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Foghorn Therapeutics Inc.? Suggest a correction